Paper

Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer

Published Nov 1, 2020 · W. Brown, P. McDonald, Oksana Nemirovsky

Cell Reports Medicine

Citations

Influential Citations

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

In Vitro StudyVery Rigorous Journal

Study Snapshot

Combinatorial treatment of KRAS and MEK inhibitors with mTORC1/2 inhibitors effectively overcomes adaptive resistance in pancreatic cancer, leading to durable inhibition of tumor growth and metastatic progression and increased survival.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer

References

Citations